Do you want to know more about the recent advances in precision oncology and potential future implications?
In this clinical topic video, medical oncologist Prof. David Hong shares his insights into recent advances in precision oncology and potential future implications and discusses two new, emerging targets, as well as two established biomarker targets and their recent clinical data.
Watch the video for an overview of:
Inhibitors for KRAS mutations
Novel agents targeting patient subsets such as those with MTAP loss
Tumour-agnostic targets such as NTRK and HER2 and how they continue to evolve and provide clinical benefit across a number of tumour types
Prof. Hong also highlights the importance of molecular profiling to ensure patients receive the most appropriate targeted therapy to improve outcomes.
Clinical takeaways
- Ongoing research is uncovering new, precise, and reliable tumour biomarkers. This has improved advanced precision medicine, promising better outcomes for people with cancer
- Inhibitors for KRAS mutations (e.g. sotorasib/adagrasib) have provided new treatment options for cancer in certain subpopulations (i.e. KRASG12C mutated); other agents targeting specific patient subsets (e.g. those with MTAP loss) may expand targeted therapy options
- Evolving targets like NTRK and HER2 are benefiting multiple cancer types
- The expansion of new biomarkers and targeted therapies highlights the importance of molecular profiling using NGS and knowing which treatment option is best suited to individual patients
Find out more about this programme and download the accompanying slides on our website: https://cor2ed.com/precision-oncology-connect/programmes/recent-advances-precision-oncology/
This content is intended for healthcare professionals only.
Published December 2024.
Follow us on social media: X: https://x.com/PresOnc_Connect
LinkedIn: https://www.linkedin.com/company/ntrk-connect/
Don’t forget to follow the COR2ED account above to see all of our new educational videos as soon as they are released.
The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This video is supported by an Independent Medical Education Grant from Bayer.
This video was developed by https://cor2ed.com/
In this clinical topic video, medical oncologist Prof. David Hong shares his insights into recent advances in precision oncology and potential future implications and discusses two new, emerging targets, as well as two established biomarker targets and their recent clinical data.
Watch the video for an overview of:
Inhibitors for KRAS mutations
Novel agents targeting patient subsets such as those with MTAP loss
Tumour-agnostic targets such as NTRK and HER2 and how they continue to evolve and provide clinical benefit across a number of tumour types
Prof. Hong also highlights the importance of molecular profiling to ensure patients receive the most appropriate targeted therapy to improve outcomes.
Clinical takeaways
- Ongoing research is uncovering new, precise, and reliable tumour biomarkers. This has improved advanced precision medicine, promising better outcomes for people with cancer
- Inhibitors for KRAS mutations (e.g. sotorasib/adagrasib) have provided new treatment options for cancer in certain subpopulations (i.e. KRASG12C mutated); other agents targeting specific patient subsets (e.g. those with MTAP loss) may expand targeted therapy options
- Evolving targets like NTRK and HER2 are benefiting multiple cancer types
- The expansion of new biomarkers and targeted therapies highlights the importance of molecular profiling using NGS and knowing which treatment option is best suited to individual patients
Find out more about this programme and download the accompanying slides on our website: https://cor2ed.com/precision-oncology-connect/programmes/recent-advances-precision-oncology/
This content is intended for healthcare professionals only.
Published December 2024.
Follow us on social media: X: https://x.com/PresOnc_Connect
LinkedIn: https://www.linkedin.com/company/ntrk-connect/
Don’t forget to follow the COR2ED account above to see all of our new educational videos as soon as they are released.
The medical experts in this video are expressing their own views and not those of COR2ED, Supporters or their institution. This video is supported by an Independent Medical Education Grant from Bayer.
This video was developed by https://cor2ed.com/
- Category
- Oncology

Be the first to comment